中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.037 seconds)

    Antibodies to TIGIT
    4.
    发明授权
    Antibodies to TIGIT 有权

    公开(公告)号：US10189902B2

    公开(公告)日：2019-01-29

    申请号：US14977789

    申请日：2015-12-22

    Applicant: Bristol-Myers Squibb Company

    Inventor： Mark F. Maurer ,  Tseng-hui Timothy Chen ,  Brigitte Devaux ,  Mohan Srinivasan ,  Susan H. Julien ,  Paul O. Sheppard ,  Daniel F. Ardourel ,  Indrani Chakraborty

    IPC: C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  A61K39/00

    Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

    ANTIBODIES TO TIGIT
    10.
    发明申请
    ANTIBODIES TO TIGIT 审中-公开
    抗体抗体

    公开(公告)号：US20160176963A1

    公开(公告)日：2016-06-23

    申请号：US14977789

    申请日：2015-12-22

    Applicant: Bristol-Myers Squibb Company

    Inventor： Mark F. Maurer ,  Tseng-hui Timothy Chen ,  Brigitte Devaux ,  Mohan Srinivasan ,  Susan H. Julien ,  Paul O. Sheppard ,  Daniel F. Ardourel ,  Indrani Chakraborty

    IPC: C07K16/28

    CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/466

    Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

    Abstract translation: 本发明提供了结合人TIGIT（具有Ig和ITIM结构域的T细胞免疫受体）的抗体或其抗原结合片段，以及这些抗体或片段在治疗应用中的用途，例如用于治疗癌症或慢性 病毒感染。 这种治疗方法包括与其它免疫调节受体相互作用的抑制剂如PD-1 / PD-L1相互作用的联合治疗。 本发明还提供了编码抗体的重链和/或轻链可变区的多核苷酸，包含编码抗体的重链和/或轻链可变区的多核苷酸的表达载体，包含载体的细胞，以及制备抗体或 片段通过从细胞表达。

Patent Agency Ranking